{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:44:50Z","timestamp":1783723490700,"version":"3.55.0"},"reference-count":29,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mem. Inst. Oswaldo Cruz"],"abstract":"<jats:p> BACKGROUND  Benznidazole (BNZ) is the primary treatment for Chagas disease. While pharmacokinetic studies of BNZ began in the 1970s, its metabolism and excretion are not fully understood. Alternatives like Benznidazol Lafepe\u00ae and Abarax\u00ae have replaced the original Radanil\u00ae.  OBJECTIVES  To compare the pharmacokinetic profiles of both currently available formulations of BNZ in adults with chronic Trypanosoma cruzi infection.  METHODS  The study involved 13 subjects each one receiving 100 mg of both presentations one week apart. Blood samples were collected over 48 hours post-administration to analyse BNZ concentration and calculate pharmacokinetic parameters.  FINDINGS  The analysis showed that both presentations had similar maximum plasma concentration and time to reach maximum plasma concentration values. Area under curve (AUC) values were slightly lower in Abarax\u00ae than Benznidazol Lafepe\u00ae. High intra-individual variability was observed, attributed to erratic absorption patterns with multiple peaks in concentration-time curves. The half-life values for both formulations were 9.1 and 8.0 h, respectively, with a significant intra-individual variability over 30%.  MAIN CONCLUSIONS  The mean difference in the AUC was lower than 10%, but exceeded the 90% confidence interval for the higher bioequivalence limit. Despite the high variability that confirms erratic absorption, the pharmacokinetic parameters of both formulations were within expected ranges.<\/jats:p>","DOI":"10.1590\/0074-02760240177","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T23:51:54Z","timestamp":1741391514000},"source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics of two pharmaceutical presentations of benznidazole in adult Trypanosoma cruzi infected population"],"prefix":"10.1590","volume":"120","author":[{"given":"Yolanda","family":"Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Administraci\u00f3n Nacional de Laboratorios e Institutos de Salud Dr Carlos G Malbr\u00e1n,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elena","family":"Marson","sequence":"additional","affiliation":[{"name":"Universidad Nacional de La Plata,  Argentina; Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas,  Argentina; Unidad Planta Laboratorio,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa Liliana","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Administraci\u00f3n Nacional de Laboratorios e Institutos de Salud Dr Carlos G Malbr\u00e1n,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Sued","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hu\u00e9sped,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Frola","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hu\u00e9sped,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Perez","family":"Lloret","sequence":"additional","affiliation":[{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas,  Argentina; Pontificia Universidad Cat\u00f3lica Argentina,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cahn","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hu\u00e9sped,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilda Graciela","family":"Prado","sequence":"additional","affiliation":[{"name":"Administraci\u00f3n Nacional de Laboratorios e Institutos de Salud Dr Carlos G Malbr\u00e1n,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9557-2137","authenticated-orcid":false,"given":"Guido Enrique","family":"Mastrantonio Garrido","sequence":"additional","affiliation":[{"name":"Universidad Nacional de La Plata,  Argentina; Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas,  Argentina; Unidad Planta Laboratorio,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Sosa-Estani","sequence":"additional","affiliation":[{"name":"Administraci\u00f3n Nacional de Laboratorios e Institutos de Salud Dr Carlos G Malbr\u00e1n,  Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2025]]},"reference":[{"issue":"9723","key":"ref1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi Jr A","year":"2010","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1590\/S0074-02762007005000093","article-title":"Epidemiology of Chagas disease in non-endemic countries: the role of international migration","author":"Schmunis GA","year":"2007","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1-2","key":"ref3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.actatropica.2009.11.003","article-title":"Chagas disease a Latin American health problem becoming a world health problem","volume":"115","author":"Schmunis GA","year":"2010","journal-title":"Acta Trop"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12916-023-02885-9","article-title":"Putting Chagas disease on the global health agenda","volume":"21","author":"BMC Medicine","year":"2023","journal-title":"BMC Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1056\/NEJMct1014204","article-title":"Antitrypanosomal therapy for chronic Chagas' disease","volume":"364","author":"Bern C","year":"2011","journal-title":"N Engl J Med"},{"issue":"9039","key":"ref6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(96)04128-1","article-title":"Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection","volume":"348","author":"de Andrade AL","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","article-title":"A critical review on Chagas disease chemotherapy","volume":"97","author":"Coura JR","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.idc.2018.10.015","article-title":"American Trypanosomiasis (Chagas Disease)","volume":"33","author":"Echeverria LE","year":"2019","journal-title":"Infect Dis Clin North Am"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.7326\/0003-4819-144-10-200605160-00006","article-title":"Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment a nonrandomized trial","volume":"144","author":"Viotti R","year":"2006","journal-title":"Ann Intern Med"},{"issue":"5","key":"ref10","first-page":"CD003463","article-title":"Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection","volume":"2014","author":"Villar JC","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","article-title":"Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of usual interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial","author":"Villar JC","year":"2019","journal-title":"Trials"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2008.04.001","article-title":"Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)","volume":"156","author":"Marin-Neto JA","year":"2008","journal-title":"Am Heart J"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008529","article-title":"Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy A systematic review and meta-analysis","volume":"14","author":"Ciapponi A","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/jac\/dks027","article-title":"Safety of benznidazole use in the treatment of chronic Chagas' disease","volume":"67","author":"Hasslocher-Moreno AM","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1542\/peds.2010-1172","article-title":"Adverse events after the use of benznidazole in infants and children with Chagas disease","volume":"127","author":"Altcheh J","year":"2011","journal-title":"Pediatrics"},{"issue":"10","key":"ref16","first-page":"1611","article-title":"Single-dose pharmacokinetics of the trypanosomicide benznidazole in man","volume":"29","author":"Raaflaub J","year":"1979","journal-title":"Arzneimittelforschung"},{"key":"ref17","first-page":"2192","article-title":"Multiple-dose kinetics of the trypanosomicide benznidazole in man","volume":"30","author":"Raaflaub J","year":"1980","journal-title":"Arzneimittelforschung"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002907","article-title":"Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults","volume":"8","author":"Altcheh J","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"e01912","DOI":"10.1128\/AAC.01912-16","article-title":"Pharmacokinetics of benznidazole in healthy volunteers and implications in future clinical trials","volume":"61","author":"Molina I","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.01401-12","article-title":"Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease","volume":"57","author":"Pinazo MJ","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1590\/0074-02760150401","article-title":"Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole","volume":"111","author":"Fern\u00e1ndez ML","year":"2016","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1128\/AAC.05018-14","article-title":"Population pharmacokinetics of benznidazole in adult patients with Chagas disease","volume":"59","author":"Soy D","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1128\/AAC.01567-16","article-title":"Systematic review and meta-analysis of the pharmacokinetics of Benznidazole in the treatment of Chagas disease","volume":"60","author":"Wiens MO","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00629-1","article-title":"Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial","author":"Bosch-Nicolau P","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"ref25","article-title":"New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial","author":"Torrico F","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17512433.2018.1509704","article-title":"Clinical and pharmacological profile of benznidazole for treatment of Chagas disease","volume":"11","author":"Kratz JM","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.actatropica.2018.02.008","article-title":"Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole","volume":"185","author":"Ferraz LRM","year":"2018","journal-title":"Acta Trop"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"e02150","DOI":"10.1128\/AAC.02150-19","article-title":"Drug-drug interaction study of Benznidazole and E1224 in healthy male volunteers","volume":"65","author":"Ribeiro I","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jcla.21615","article-title":"Development of UV\/HPLC methods for quantitative analysis of benznidazole in human plasma and urine for application in pediatric clinical studies","volume":"27","author":"Marson ME","year":"2013","journal-title":"J Clin Lab Anal"}],"container-title":["Mem\u00f3rias do Instituto Oswaldo Cruz"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0074-02762025000101104&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T23:52:06Z","timestamp":1741391526000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0074-02762025000101104&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"alternative-id":["S0074-02762025000101104"],"URL":"https:\/\/doi.org\/10.1590\/0074-02760240177","relation":{},"ISSN":["1678-8060","0074-0276"],"issn-type":[{"value":"1678-8060","type":"electronic"},{"value":"0074-0276","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e240177"}}